Erin Harris: CRISPR Gene Therapy in Children
Erin Harris, Chief Editor and Host of Cell and Gene The Podcast, shared a post on LinkedIn:
“Back in June, new research published in The New England Journal of Medicine reported encouraging results for exa-cel, a CRISPR-based therapy, in children ages 5 to 11 with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
And so I wanted to speak with Dr. Haydar Frangoul, medical director of the Pediatric Stem Cell Transplant Program at HCA Healthcare’s TriStar Centennial Children’s Hospital in Nashville, because this research raises important questions beyond the initial results.
There’s a lot to consider as gene editing moves into younger patient populations. Dr. Frangoul and I covered a lot of ground, here’s Part 1 of our conversation.
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 10:19Beverley Hunt: PE Knows No Age – Isaac’s Story
-
Nov 16, 2026, 10:08Abdul Mannan: When Normal Blood Counts Hide Iron Deficiency
-
Nov 16, 2026, 09:47Ankit Kumar: A Memorable Experience at Haematocon 2026
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation